STEM CELL IMMUNOMODULATORY THERAPY FOR COVID-19 INFECTION

摘要

The disclosure provides methods of treating coronavirus infections (e.g., COVID-19) by administering hematopoietic stem cells, with or without an immune checkpoint inhibitor (e.g., PD-1 antagonist). The disclosure also provides methods of treating coronavirus infections (e.g., COVID-19) by adoptive cell transfer of polyclonal T cells and coronavirus- specific T cells (e.g., SARS-CoV-2-specific T cells).